drug
everolimus SR
Preclinicalupdated 3mo agoby Postsurgical Therapeutics Inc
Preclinicalcommunity read0 votes
🐶 often sniffed alongside
top 8- drugEVEROLIMUS36 co-mentions · 24 sources
- drugeverolimus ODT36 co-mentions · 24 sources
- drugZortress36 co-mentions · 24 sources
- tagApproval16 co-mentions · 8 sources
- tagAdCom15 co-mentions · 11 sources
- tagPMA Approval15 co-mentions · 11 sources
- tagSmall Molecule8 co-mentions · 8 sources
- companyPar Pharmaceutical Inc5 co-mentions · 5 sources
all catalysts(0)
nothing on the calendar yet
Trials studying everolimus SR
- phase1Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer
- phase3Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- phase2A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
- —REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
- phase2Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
- phase4A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
- phase2Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
News(3)
- FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issuesITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.biospace · 6d ago
- STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentThe FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.stat · 7d ago
- Opinion: I’m a heart transplant recipient. I’m haunted by ‘ghost approval’ for medication I need to survive“On paper, I have insurance coverage. In real life, I don’t have access. That’s what I call ‘ghost approval,’” writes patient advocate Payton Herres.stat · 3mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that